← Eichor
Condition: Myopia Child Myopia Progression Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myopia Child Myopia Progression

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elo
Phase 3 · 1 location(s) · Laboratorios Sophia S.A de C.V. · NCT06389110
The Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children
Phase 3 · 1 location(s) · Aston University · NCT07535749
Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Prog
NA · 1 location(s) · Beijing Tongren Hospital · NCT07323251
Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses
NA · 1 location(s) · SightGlass Vision, Inc. · NCT07229352
Factors Influencing Physiological Hyperopia in Children
Phase N/A · 1 location(s) · Beijing Tongren Hospital · NCT06498947
Correcting Myopia Among Secondary School Children to Increase Academic High School Attendance Rates in Rural Communities
NA · 3 location(s) · Queen's University, Belfast · NCT04077086
Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)
Phase 3 · 11 location(s) · Ocus Innovation Ireland Limited · NCT07028827
Pharmacological and Non-pharmacological Treatment Effects on Children With Different Predicted Myopia Progression Rate
NA · 1 location(s) · The Hong Kong Polytechnic University · NCT06282848
Association of Genetic Variants With Myopia
Phase N/A · 2 location(s) · Beijing Visionly Plus Eye Hospital · NCT07030153
Electronic Spectacles Versus Low Dose Atropine in Young Myopes
NA · 1 location(s) · Kubota Vision Inc. · NCT06034379
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametro
NA · 11 location(s) · Bausch & Lomb Incorporated · NCT06305663
The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatri
Phase 3 · 25 location(s) · Oupushifang Pharmaceutical Technology Co., Ltd. · NCT06708156
Effect of MiYOSMART iQ Spectacle Lenses on Myopia Progression in Children
NA · 1 location(s) · Hoya Lens Rus LLC · NCT07387159
Wearability of and Myopia Progression With ZEISS MyoCare Spectacle Lenses
NA · 1 location(s) · ZEISS Vision Care · NCT07021560
MAD Trial: Myopia Atropine Dose
Phase 3 · 20 location(s) · Erasmus Medical Center · NCT05667454
Inhibition of Myopia Progression With Optical Devices
Phase N/A · 1 location(s) · Semmelweis University · NCT07698977
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
NA · 14 location(s) · SightGlass Vision, Inc. · NCT06034327
Evaluation of the Effectiveness of a New Generation of Myopia Control Lens on the Progression of Myopia in Children Aged
NA · 1 location(s) · Essilor International · NCT07462897
A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06151587
Extension Study on Safety and Rebound Effect of SAT-001 for Myopia in Children
Phase N/A · 5 location(s) · S-Alpha Therapeutics, Inc. · NCT06742268
Atropine in the Treatment of Myopia Study in Malaysia
Phase 3 · 2 location(s) · IDB VisionCare SDN BHD · NCT07329777
A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control
Phase 3 · 17 location(s) · Jaeb Center for Health Research · NCT07095894
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.